Crowley John F's Form 4 filing
Amicus Therapeutics, Inc. (FOLD) · filed Sep 17, 2021
- Accession no.
- 0001209191-21-056689
- Filed
- Sep 17, 2021
- Trade date
- Sep 15, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $243.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Crowley John FCIK 0001400973 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2021 | Common Stock | MOption exerciseAcquired | +22,000 | $4.38 | +$96,360 | 861,845 | Direct | |
| Sep 15, 2021 | Common Stock | SSaleDisposed | −22,000 | $11.08F2 | −$243,760 | 839,845 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2021 | Common Stock | MOption exerciseDisposed | −22,000 | $0.00 | $0 | 46,935 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $10.83 to $11.18 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.